Find out how higher dose aflibercept may reduce injection burden while preserving vision in retinal vasculopathy.

The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...

Bioeq AG will be responsible for the development, manufacturing, regulatory registration and ongoing supply of the biosimilar product.

In July 2025, Novartis Pharmaceuticals conducted a study is to assess the effect of Iptacopan to prevent conversion of early ...

Zydus Lifesciences has partnered with Swiss firm Bioeq to commercialise NUFYMCO in the US following FDA approval on December ...

GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight. But they need to be taken for years, ...

In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to ...

Treatments are available for dry AMD patients who also have geographic atrophy, but until the FDA's recent authorization of ...

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in ...

Kalaris Therapeutics, Inc. reported improved Q3'25 results, with a net loss of $11.9M and $77M in cash. Click here to read why KLRS stock is a Buy.

In this video from the American Academy of Ophthalmology meeting, Lejla Vajzovic, MD, discusses updates on home OCT for neovascular age-related macular degeneration.

Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases, today announced that Jason ...